Clinical Trial Update: RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study [Phase 2]

View source ↗

Summary

Phase II trial evaluating RC48 in combination with bevacizumab or pyrotinib for HER2-positive metastatic breast cancer after failure of T-DXd is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pyrotinib (pyrotinib)
• RC48 (disitamab vedotin)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: HER2 + Breast Cancer | Phase 2 | Status: RECRUITING